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aEgyptBackground: Epidemiologic evidence suggests that the complications of diabetes begin early in the progression from
normal glucose tolerance to frank diabetes. Prediabetes is defined as people with impaired fasting glucose (IFG) or
impaired glucose tolerance (IGT), some of whom in fact already have the characteristic microvascular changes resulting
from diabetes itself.
Methods and results: This studywas conducted on 108 patients presenting to Ain ShamsUniversity Catheterization
Laboratory for electivepercutaneous coronary interventionusingbaremetal stents (48diabeticpatients, 30pre-diabetic
patients and 30non-diabetic patients). All patients underwent baremetal stent deployment either precededbyballoon
dilatation or not. Follow-up was done at three and six months for major adverse cardiac & cerebral events (cardiovas-
cular death, acute coronary syndrome, cerebrovascular stroke, target vessel revascularization).
Results: Our findings demonstrate that therewas no statistically significant difference between patients of the three
different study groups regarding composite end point of death, stroke, acute coronary syndrome and target vessel
revascularization at three months follow-up (diabetics = 18.8%, pre-diabetics = 13.3%, non diabetics = 3.3%, p-
value = 0.1), but there was a highly statistical difference between them regarding acute coronary syndrome (diabet-
ics = 43%, pre-diabetics = 26%, non diabetics = 10%, p-value = 0.006) at six months follow-up.
Conclusion: Prediabetes, though not a disease entity by itself is associated with of risk for both macrovascular and
increasingly, microvascular pathology. It is important to identify these conditions to prevent incident diabetes and to
takemeasures to stop thevascular complications.Our studyfindings revealed that complications ofdiabetesmaybegin
early as patients are suffering impaired glucose homeostasis, which warrants further evaluation in larger studies.
 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Keywords: Angioplasty, Diabetes, PrediabetesIntroduction
Aworldwide pandemic of diabetes is well ad-vanced. People with diabetes are vulnerable
to multiple and complex medical complications.
These complications include both cardiovascular
disease (CVD) (heart disease, stroke, and periphe-1016–7315  2012 King Saud University.
Production and hosting by Elsevier B.V. All rights reserved.
Peer review under responsibility of King Saud University.
URL: www.ksu.edu.sa
http://dx.doi.org/10.1016/j.jsha.2012.12.003ral vascular disease) and microvascular disease
(i.e., retinopathy, neuropathy and microalbuminu-
ria). Most patients with diabetes die of CVD [1].
Epidemiologic evidence suggests that the
complications of diabetes begin early in the pro-
gression from normal glucose tolerance to frank
diabetes [1]. Prediabetes is defined as people withProduction and hosting by Elsevier
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cose tolerance (IGT), some of whom in fact already
have the characteristic microvascular changes
resulting from diabetes itself [2,3].
Worldwide, the number of peoplewith prediabe-
tes is estimated to be 314million and is projected to
be 418million in 2025.As theprevalence of andpro-
gression to diabetes continues to increase, diabe-
tes-related morbidity and mortality have emerged
as major public health care issues [4].
Diabetes is expensive, associated with direct
costs related to diabetes, diabetes complications,
and general medical care and indirect costs are
from illness, disability, and premature mortality
[4]. Prediabetes raises short-term absolute risk of
type 2 diabetes by 3–10-fold, with some popula-
tions exhibiting greater risk than others [5,6].
Early identification and treatment of persons
with prediabetes have the potential to reduce or
delay the progression to diabetes [7–11] and re-
lated CVD [12,13] and microvascular disease [8].
Despite the clear origins of diabetes-related com-
plications early in the pre-diabetic state, few rec-
ommendations have been made for the diagnosis
andmanagement of patients with prediabetes [14].
There are differences in opinion among health
care professionals regarding the therapeutic ap-
proach to treating people with prediabetes. Many
of these people already have diabetes-related
complications, yet there are no defined goals and
targets of treatment in prediabetes for the many
risk factors, which include glucose levels, weight,
blood pressure, and lipid levels [15].Patients and methods
The current study was conducted on 108 patients
presented to Ain-Shams university catheter labo-
ratory for elective percutaneous coronary interven-
tion from the period from September 2009 to June
2010. All patients signed consent forms for both
the coronary PCI as well as the study and follow-
up. The Ethical Committee of the Faculty of Medi-
cine, Ain Shams University approved the study.
The study complies with the Declaration of Hel-
sinki and did not endanger thewell being of the pa-
tients. There was no funding for the study. The
authors have no conflicts of interest to declare.
Patients were divided into three groups:
- Group 1 included:
Type II diabetes mellitus patients with fasting
blood sugarP126 mg/dl and 2 h postprandial
blood sugarP200 mg/dl and/or are receiving
oral hypoglycemicmedications or insulin [16].- Group 2 included:
Prediabetic patients with fasting blood sugar
100–125 mg/dl and/or 2 h postprandial blood
sugar 140–199 mg/dl [16].
- Group 3 included:
Patients with normal fasting blood sugar
<100 mg/dl and 2 h postprandial blood sugar
<140 mg/dl [16].
Exclusion criteria
- Type I diabetes mellitus.
- Patients >70 years old.
- Patients undergoing percutaneous coronary
intervention by drug-eluting stents.
Each patient was subjected to the following:
1. Full medical history taking:
2. Clinical examination
(a) General and local cardiac examination:
Including measurement of waist circumfer-
ence by locating the upper hip bone and plac-
ing a measuring tape around the abdomen
(ensuring that the tapemeasure is horizontal).
(b) Calculation of body mass index according to
the following equation [17].BMI ¼ mass ðkgÞðheightðmÞÞ23. Laboratory investigation
For all patients serum creatinine, fasting and
2 h post prandial glucose levels were measured.
4. Echocardiography
Full echocardiography was done to all patients
using a GE VIVID 5 echocardiogram machine
and 2.5 MHz probe with assessment of the fol-
lowing parameters:
 Ejection fraction by modified Simpson’s
method.
 Left ventricular end diastolic & systolic
dimensions.
 Inter ventricular septum & posterior wall
thickness.
 Segmental wall motion score index (WMSI)
was analyzed using a 16 segment model and
calculated by the total score/number of seg-
ments analyzed [18].
5. Coronary angiography and percutaneous coro-
nary intervention
 All patients were given a loading dose of Clopi-
dogrel of 600 mg at least 12 h before the
procedure.
Figure 1. Chart showing the distribution of ischemic heart disease
risk factors among the different study groups. DM = Diabetes
Mellitus, PRE DM = Prediabetes Mellitus, NON DM = Nondiabetics,
HTN = Hypertension, FH isch = Family History of ischemic heart
disease, dyslipid = Dyslipidemia, pre PCI = previous percutaneous
coronary intervention, pre CABG = previous coronary artery bypass
grafting.
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using six French sheaths.
 Unfractionated heparin (UFH) was adminis-
tered at a dose of 100 IU/kg for all patients just
before PCI.
 All patients underwent bare metal stent
deployment either preceded by balloon dila-
tation or not.
 All patients received combined anti-platelet
therapy with acetylsalicylic acid and a clopi-
dogrel for 3–6 month after the procedure.
6. Follow-up at 3 and 6 months
For major adverse cardiac & cerebral events
(cardiovascular death, acute coronary syn-
drome, cerebrovascular stroke, target vessel
revascularization).
7. Statistical analysis
Data were collected, verified, revised and edi-
ted on a personal computer. They were then
statistically analyzed using SPSS statistical
package version 16.
The following tests were performed:
Mean and standard deviation (SD).
 T-test for independent samples.
 Chi square test (v2).
 ANOVA test.
 Pearson correlation coefficient (r).
⁄ p value more than 0.05 was considered non-
significant while p value less than 0.05 was consid-Table 1. Showing age and gender distribution in the different stud
Diabetics (48) Prediabeti
Age (years) 57 ± 7.5 55 ± 9
Females (%) 15 (31%) 10 (33%)
Males (%) 33 (69%) 20 (67%)
Table 2. Comparing the different groups regarding other risk facto
Diabetics (30)
Smoking
-Never smoked 18 (38%)
-Current smoker 22 (46%)
-Exsmoker 8 (16%)
HTN 35 (73%)
Dyslipidemia 33 (69%)
Positive family history for ischemia 29 (60%)
Positive family history for diabetes mellitus 27 (56%)
Renal impairment 5 (10%)
Previous CVS 1 (2%)
PVD 3 (6%)
Previous ACS 31 (65%)
Previous PCI 11 (23%)
Previous CABG 2 (4%)
HTN = hypertension, CVS = cerebrovasculsr stroke, PVD = peripheral vascu
nary intervention, CABG = coronary artery bypass grafting.ered significant and p value less than 0.01 was
considered highly significant.Results
A-the demographic data
All patients were age and sex matched (Table 1).
B-risk factors
 In the diabetic patients group, the mean
duration of diabetes was 6 ± 6.7 years.y groups.
cs (30) Non diabetics (30) p-value
53 ± 10 >0.05
10 (33%) >0.05
20 (67%) >0.05
rs of ischemic heart disease and co-morbidities.
Prediabetics (30) Non diabetics (30) p-value
9 (30%) 8 (27%) >0.05
18 (60%) 16 (53%)
3 (10%) 6 (20%)
15 (50%) 11(37%) 0.05
17 (57%) 9 (30%) 0.04
11 (37%) 7 (23%) 0.04
7 (23%) 6 (20%) 0.001
1 (3%) 2 (7%) >0.05
0 (0%) 1 (3%) >0.05
2 (7%) 1 (3%) >0.05
26 (87%) 20 (66%) >0.05
10 (33%) 2 (7%) >0.05
1 (3%) 0 (0%) >0.05
lar disease, ACS = acute coronary syndrome, PCI = percutaneous coro-
Table 3. Shows the mean ± standard deviation of systolic, diastolic blood pressure, heart rate, waist circumference, height, weight,
body mass index, serum creatinine, and different echocardiographic findings in the different groups.
Diabetics (48) Prediabetics (30) Non diabetics (30) p-value
Systolic BP (mmHG) 135 ± 15 135 ± 20 123 ± 15 0.004
Diastolic BP (mmHG) 86 ± 11 84 ± 11 80 ± 11 0.036
HR (bpm) 74 ± 8 76 ± 9 73 ± 6 >0.05
Waist circumference (cm)
Males 106 ± 6 104 ± 6 105 ± 5 >0.05
Females 94 ± 5 93 ± 3 92 ± 4 >0.05
Height (cm) 166 ± 8 169 ± 7 170 ± 9 >0.05
Weight (kg) 85 ± 11 80 ± 12 85 ± 10 >0.05
BMI (kg/cm2) 30 ± 5 28 ± 4 29 ± 3 >0.05
Serum creatinine (mg/dl) 1.1 ± 0.4 1.05 ± 0.3 1.01 ± 0.3 >0.05
Ejection fraction (%) 53 ± 5 52 ± 8 51.5 ± 5 >0.05
Interventricular septum (mm) 11 ± 2 10 ± 2 10 ± 2 >0.05
Posterior wall (mm) 11 ± 2 10 ± 2 10 ± 2 >0.05
Left ventricular end systolic dimension (mm) 37 ± 9 38 ± 8 36 ± 6 >0.05
Left ventricular end diastolic dimension (mm) 53 ± 5 52 ± 8 51 ± 5 >0.05
WMSI 1.16 ± 0.19 1.15 ± 0.17 1.14 ± 0.14 >0.05
BP = blood pressure, BMI = body mass index, WMSI = wall motion score index.
Table 4. Showing distribution of lesions number, type of lesions, number of affected vessels in the different study groups, and the
mean of contrast volume used and time of procedure between different study groups.
Diabetics (48) Prediabetics (30) Non diabetics (30) p-value
LAD 42 (87.5%) 23 (77%) 22 (73%) >0.05
Diagonal branch 3 (6%) 2 (7%) 5 (17%) >0.05
LCX 20 (42%) 6 (20%) 6 (20%) >0.05
OM 9 (19%) 2 (7%) 2 (7%) >0.05
RCA 24 (50%) 15 (50%) 15 (50%) >0.05
PDA 3 (6%) 0 (0%) 0 (0%) >0.05
PL 2 (4%) 1 (3%) 0 (0%) >0.05
Type (A) 6 (12.5%) 3 (10%) 3 (10%) >0.05
Type (B) 31 (65%) 17 (57%) 22 (73%) >0.05
Type (C) 11 (22.5%) 10 (33%) 5 (17%) >0.05
1 Vessel 18 (37.5%) 18 (60%) 15 (50%) >0.05
2 Vessel 18 (37.5%) 8 (26.7%) 12 (40%) >0.05
3 Vessel 12 (25%) 4 (13.3%) 3 (10%) >0.05
Contrast volume (ml) 239 ± 48 195 ± 45 192 ± 45 >0.05
Procedure time (minutes) 39 ± 11 32 ± 7 31 ± 10 >0.05
LAD = left anterior descending, LCX = left circumflex, OM = obtuse marginal branch, RCA = right coronary artery, PDA = posterior descending
artery, PL = posterolateral branch.
Table 5. Showing number of patients who underwent pre-dilation by balloon angioplasty before stent deployment, mean of pressure
of balloon inflation, and the mean length and diameter of balloons and stents used in percutaneous coronary intervention in the
three groups.
Diabetics (48) Prediabetics (30) Non diabetics (30) p-value
Pre-dilation balloon % of total 30 (27%) 12 (11%) 7 (6.5%) 0.003
Pressure of balloon (atm) 14 ± 3 11 ± 1 11 ± 1 0.02
Diameter of balloon (mm) 2 ± 0.5 2 ± 0.5 2 ± 0.5 1
Length of stent (mm) 20 ± 7 18 ± 5 18 ± 6 >0.05
Diameter of stent (mm) 3 ± 0.5 3 ± 0.5 3 ± 0.25 >0.05
Mean pressure of stent deployment in the three different groups was 14 ± 1.
There was significant statistical difference between groups regarding pressure of inflation of balloon.
There was no significant statistical difference between the different study groups regarding balloon and stent length, balloon and stent diameter.
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Table 6. Showing the major adverse cardiac & cerebral events in the different groups at 3 months follow-up.
Diabetics (48) Prediabetics (30) Non diabetics (30) p-value
Death 1 (2%) 0 (0%) 0 (0%) 0.5
ACS 7 (14%) 3 (10%) 1 (3%) 0.2
Cerebrovascular stroke 1 (2%) 0(0%) 0 (0%) 0.5
Target vessel revascularization 3 (6%) 2 (7%) 0 (0%) 0.3
Instent restenosis 2 (4%) 1 (3.3%) 0 (0%) 0.3
De novo lesions 1 (2%) 1 (3.3%) 0 (0%) 0.4
Composite endpoint (%) 9 (18.8%) 4 (13.3%) 1 (3.3%) 0.1
ACS = acute coronary syndrome.
Table 7. Showing the major adverse cardiac & cerebral events in the three groups at 6 months follow-up.
Diabetics (48) Prediabetics (30) Non diabetics (30) p-value
Death 3 (6%) 1 (3%) 0 0.2
ACS 21 (43%) 8 (27%) 3 (10%) 0.006
Cerebrovascular stroke 1 (2%) 0 (0%) 0 (0%) 0.5
Target vessel revascularization 7 (14.5%) 4 (13%) 1 (3%) 0.1
Instent restenosis 5 (10.4%) 3 (10%) 0 (0%) 0.08
De novo lesions 2 (2%) 1 (3.3%) 0 (0%) 0.2
Composite endpoint (%) 21 (43%) 10 (33%) 3 (10%) 0.007
ACS = acute coronary syndrome.
There was no statistical difference between diabetics and pre-diabetic groups regarding major adverse cerebral and cardiac events.
Table 8. Showing comparison between diabetics and predia-
betics groups regarding major adverse cardiac & cerebral
events at 6 months follow-up.
Diabetics
(48)
Prediabetics
(30)
p-
value
Death 3(6%) 1 (3%) 0.64
ACS 21 (43%) 8 (27%) 0.32
Cerebrovascular stroke 1 (2%) 0 (0%) 1
Target vessel
revascularization
7 (14.5%) 4 (13%) 1
Composite endpoint (%) 21 (43%) 10 (33%) 0.32
ACS = acute coronary syndrome.
There was no statistical difference between diabetics and non diabetic
groups regarding major adverse cerebral and cardiac events except
those regarding acute coronary syndrome which was highly statistically
significant.
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lin while 79% were on oral hypoglycemic.
 Regarding other risk factors and co-
morbidities:Table 9. Showing comparison between diabetics and non-diabetic
6 months follow-up.
Diabetics (48)
Death 3 (6%)
ACS 21 (43%)
Cerebrovascular stroke 1 (2%)
Target vessel revascularization 7 (14.5%)
Composite endpoint % 21(43%)
ACS = acute coronary syndrome.
There was no statistical difference between non diabetic and pre-diabetic gr
regarding acute coronary syndrome and which was statistically significant.There was a statistically significant difference
between different groups regarding family history
for ischemic heart disease, hypertension and dysl-
ipidemia. This difference was highly significant
regarding family history for diabetes mellitus with
more affectation of diabetic patients group but
there was no statistical difference between them
for the other factors. (Table 2, Fig. 1) (see Tables
3–12)
C-examination and echocardiographic findings
There was a statistical difference between the
three study groups regarding systolic and diastolic
blood pressure.
There was no statistical difference between the
groups regarding heart rate, waist circumference,
height, weight and body mass index.
There was no statistical difference between the
three study groups regarding the values of serum
creatinine.groups regarding major adverse cardiac & cerebral events at
Non diabetics (30) p-value
0 0.15
3 (10%) 0.002
0 1
1 (3%) 0.14
3 (10%) 0.002
oups regarding major adverse cerebral and cardiac events except those
Table 10. Showing comparison between pre-diabetics and non
diabetics groups regarding major adverse cardiac & cerebral
events at 6 months follow-up.
Prediabetics
(30)
Non
diabetics
(30)
p-value
Death 1 (3%) 0 1
ACS 8 (27%) 3 (10%) 0.05
Cerebrovascular
stroke
0 0 1
Target vessel
revascularization
4 (13%) 1 (3%) 0.35
Composite endpoint
%
10 (33%) 3 (10%) 0.047
ACS = acute coronary syndrome.
Independent predictors: – Independent predictors of acute coronary
syndrome at six months by multivariate analysis of gender, risk factors
(D.M, HTN, dyslipidemia, smoking), stent length and diameter were
male gender, diabetes mellitus, smoking, stent length more than 13 mm
and stent diameter equal or less than 2.75 mm.
Table 11. Showing independent predictors of acute coronary
syndrome at 6 months.
Relative
risk
95% CI p-value
Male gender 2.44 1.434.18 p = 0.0011
Diabetes mellitus 2.31 1.51–2.21 p = 0.0098
Smoking 2.47 1.314.69 p = 0.0054
Stent length >13 mm 1.80 1.033.14 p = 0.0377
Stent diameter
62.75 mm
2.20 1.293.76 p = 0.0040
CI = confidence interval.
Independent predictors of target vessel revascularization at 6 months
by multivariate analysis of gender, risk factors (D.M, HTN, dyslipide-
mia, smoking), stent length and diameter were of the male gender,
smoking and stent diameter equal or less than 2.75 mm.
Table 12. Showing independent predictors of target vessel
revascularization at 6 months.
Relative
risk
95% CI p-value
Male gender 3.6400 1.213.85 p = 0.0097
Smoking 5.3846 1.2423.431 p = 0.0248
Stent diameter
62.75 mm
1.9360 1.1553.246 p = 0.0125
CI = confidence interval.
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different study groups regarding the echocardio-
graphic data.
F-coronary angiography and percutaneous
coronary intervention data
There was no statistically significant difference
between the groups regarding lesion distribution,
type of lesions and number of affected vessels.G-the patients were followed up for three months
 There was no statistical difference between
the three groups regarding major adverse
cerebral and cardiac events.
G-the patients were followed up again at 6 months
There was no statistical difference between the
three groups regarding major adverse cerebral
and cardiac events except those regarding acute
coronary syndrome which was highly statistically
significant. Although cardiovascular mortality (at
three months diabetics = 2%, pre-diabetics = 0%,
non diabetics = 0%, p-value = 0.5) and (at
6 months diabetics = 6%, pre-diabetics = 3%, non
diabetics = 0%, p-value = 0.3) and target vessel
revascularization (at 3 months diabetics = 6.2%,
pre-diabetics = 6%, non diabetics = 0%, p-value =
0.3) and (at 6 months diabetics = 14.5%, pre-dia-
betics = 13.3%, non diabetics = 3.3%, p-value = 0.1)
did not show statistical significant difference be-
tween the different study groups neither at
3 months nor at 6 months follow-up, the p-value
was more towards significance at 6 months fol-
low-up.Discussion
Diabetes mellitus is a well-recognized disease
that is associated with a poor outcome after surgi-
cal or percutaneous revascularization in patients
with coronary artery disease. The reasons for
higher mortality rates, greater incidence of MI
and the need for additional revascularization pro-
cedures in diabetics treated with percutaneous or
surgical revascularization are multi factorial.
It is well known that people with prediabetes
have an increased risk of progression to type 2
diabetes mellitus as stated in ACE/AACE consen-
sus statement, 2008 [16].
In 2010 M.O. Lima-Filho et al. [19] compared pa-
tients with and without dysglycemia regarding
restenosis after percutaneous coronary interven-
tion using bare-metal stents by identified by intra-
vascular ultrasound (IVUS) and angiographic
parameters. Seventy consecutive patients (77 le-
sions) selected and evaluated by the oral glucose
tolerance test after a successful percutaneous cor-
onary intervention (PCI) with a bare-metal stent.
Six-month IVUS and angiogram follow-up were
performed. Thirty-nine patients (55.7%) had dys-
glycemia. The restenosis rate in the dysglycemic
group was 37.2% vs. 23.5% in the euglycemic
group (P = 0.299). Fasting plasma glucose (FPG):
6108.8 mg/dL (RR = 0.53; 95% CI = 0.13–0.75;
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tients treated with a bare-metal stent.
In the Japanese Funagata Diabetes Study [20],
survival analysis concluded that IGT was a risk
factor for CVD. In 2010, Finnish Study [21], IGT
at baseline was an independent risk predictor of
incident CVD and premature all-cause and car-
diovascular mortality, a finding not confounded
by the development of clinically diagnosed diabe-
tes during follow-up.
Our study is one of the first studies to prospec-
tively evaluate the impact of pre diabetes on out-
come of patients undergoing elective
percutaneous coronary intervention regarding
major adverse cerebral and cardiac events in rela-
tion to diabetic and non diabetic patients. 108 pa-
tients were included in this study (48 diabetic
patients, 30 pre-diabetic patient and 30 non-dia-
betic level patients). Our findings demonstrate
that there was no statistically significant differ-
ence between patients of the three different study
groups (diabetics = 18.8%, pre-diabetics = 13.3%,
non diabetics = 3.3%, p-value = 0.1) regarding
composite end point of death, stroke, acute coro-
nary syndrome and target vessel revascularization
at 3 months follow-up, the small sample size and
short duration of the study limited the ability to
detect a difference at this point, but there was
high statistical difference between them regarding
acute coronary syndrome (diabetics = 43%, pre-
diabetics = 26%, non diabetics = 10%, p-va-
lue = 0.006) at 6 months follow-up.
Although cardiovascular mortality (at 3 months
diabetics = 2%, pre-diabetics = 0%, non diabet-
ics = 0%, p-value = 0.5) and (at 6 months diabet-
ics = 6%, pre-diabetics = 3%, non diabetics = 0%,
p-value = 0.3) and target vessel revascularization
(at 3 months diabetics = 6.2%, pre-diabetics = 6%,
non diabetics = 0%, p-value = 0.3) and (at
6 months diabetics = 14.5%, pre-diabetics = 13.3%,
non diabetics = 3.3%, p-value = 0.1) did not show
a statistically significant difference between the
three study groups neither at 3 months nor at
6 months follow-up, the p-value was more to-
wards significance at 6 months follow-up, which
warrants the need of further evaluation in longer
follow-up intervals e.g. at 12 months and 5 years
and larger study population.
Diabetics had a higher incidence of major ad-
verse cardiac events in comparison to non diabet-
ics (composite end point of diabetics = 43%, non
diabetics = 10%, p-value = 0.002), and pre-diabet-
ics also had higher incidence of major adverse car-
diac events in comparison to non diabetics
(composite end point of pre-diabetics = 33%, nondiabetics = 10%, p-value = 0.047). When compar-
ing the diabetic and pre-diabetic patients groups
there was no statistical difference between these
2 groups even regarding acute coronary syndrome
(composite end point of diabetics = 43%, pre-dia-
betics = 33%, p-value = 0.32).
In 2003, O’Neill et al. investigated the relation
between glycemic levels as measured by hemoglo-
bin A1c and outcome after elective percutaneous
coronary intervention (PCI) of a single vessel de
novo coronary artery narrowing. The primary
end point of this study was the incidence of a ma-
jor adverse cardiac event (MACE) (cardiovascular
mortality, myocardial infarction, or need for target
vessel revascularization [TVR]) within 12 months
of the index intervention [22].
Our study included patients according to the re-
cently revised AACE/ADA/WHO definition of
diabetes and pre diabetes which is diabetes melli-
tus [16]: patients with fasting blood sugar
P126 mg/dl and 2 h postprandial blood sugar
P200 mg/dl, Pre-diabetes: patients with fasting
blood sugar 100–125 mg/dl and/or 2 h postpran-
dial blood sugar 140–199 mg/dl while in O’Neill
et al. study, they divided patients according to
hemoglobin A1c level into diabetics, non-diabetic
patients with hemoglobin A1c level <6%, and
non-diabetic patients with hemoglobin A1c level
6–7% [22].
Outcome at 12 months: as expected, 209 diabetic
patients had a higher incidence of MACEs (cardio-
vascular mortality, repeat infarction, or TVR) com-
pared with 204 non-diabetic patients with
hemoglobin A1c level <6 (35% vs. 24%, p-va-
lue = 0.02). Their results are in agreement with
our results as regards the acute coronary
syndrome (diabetics = 43%, non diabetics = 10%,
p-value = 0.002) at 6 months follow-up, but in dis-
agreement to our study regarding cardiovascular
mortality at 6 months diabetics = 6%, non diabet-
ics = 0%, p-value = 0.15) and target vessel revascu-
larization (at 6 months diabetics = 14.5%, non
diabetics = 3.3%, p-value = 0.14).
In the O’Neill et al. study 87 non-diabetic pa-
tients with an abnormal hemoglobin A1c level
(6–7%) had a significantly higher rate of major ad-
verse cardiac events (33% vs. 22%, p-value = 0.04),
target vessel revascularization (31% vs. 19%, p-va-
lue = 0.02), and cardiovascular mortality (4.6% vs.
0.5%, p-value = 0.03) compared with non-diabetic
patients with hemoglobin A1c levels <6%) which
is in disagreement also with our study regarding
cardiovascular mortality cardiovascular mortality
(at 6 months pre-diabetics = 3%, non diabet-
ics = 0%, p-value = 1) and target vessel revascular-
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non diabetics = 3.3%, p-value = 0.35). The rates of
cardiovascular mortality, repeat infarction, and
TVR in non-diabetics with an abnormal hemoglo-
bin A1c level were similar compared with diabetic
patients [22].
This difference in both results could be attrib-
uted to the difference between the two studies in
the following:
 Longer follow-up interval and larger study
population.
 Mean age was (non diabetics = 53 ± 10,
pre-diabetics = 55 ± 9, diabetics = 57 ± 7.5, p-
value = 0.1) in this study while it was
(patients with hemoglobin A1c <6% =
65 ± 11, patients with hemoglobin A1c
6–7% =68 ± 9, diabetic patients = 66 ± 10, p-
value = 0.88) in O’Neill et al. study [22].
 Prior percutaneous coronary intervention
was (patients with hemoglobin A1c
<6% = 34%, patients with hemoglobin A1c
6–7% = 48%, diabetic patients = 45%, p-
value = 0.36) in O’Neill et al. study [22] which
is in disagreement to our study (non diabet-
ics = 6%, pre-diabetics = 33%, diabet-
ics = 23%, p-value = 0.39).
 Prior coronary artery bypass grafting was
(patients with hemoglobin A1c <6% = 19%,
patients with hemoglobin A1c 6–7% = 23%,
diabetic patients = 29%, p-value = 0.15) in
O’Neill et al. study (281) whic h is in dis-
agreement to our study (non diabetics = 0%,
pre-diabetics = 3.3%, diabetics = 4.1%, p-
value = 0.8) in our study.
In the past few years, several studies were direc-
ted to test the effect of diabetes mellitus on the
outcome of patients revascularized by percutane-
ous coronary intervention.
In the ARTS (Arterial Revascularization Therapy
Study) trial conducted by Patrick W. Serruys et al.,
[23] a total of 1,205 patients with the potential for
equivalent revascularization were randomly as-
signed to CABG (n: 605) or treated with bare metal
stent implantation (n: 600). The primary clinical
end point was freedom from major adverse car-
diac and cerebrovascular events (MACCE) at one
year; MACCE at five-year follow-up constituted
the final secondary end point. The study popula-
tion included 208 diabetic patients. The reduced
event-free survival at one year in diabetic patients
treated with stenting as compared with diabetic
patients treated with CABG (63.4% vs. 84.4%, p-
value < 0.001) and non-diabetic patients treated
with stents (76.2%, p-value = 0.04) was due to a
higher incidence of repeat revascularization.Diabetic patients (19% of this group) had a sig-
nificantly higher mortality rate than non-diabetic
patients (13.4% vs. 6.8%; p-value = 0.03; RR, 1.98;
95% CI, 1.11–3.52). This percentage is higher in
Patrick W. Serruys et al. study [23] than that of
our study (at 6 months diabetics = 6%) which can
be due to higher mean age was (61 ± 10 years),
longer follow-up interval and larger study
population.
In another study conducted by Roberto A. Cor-
pus et al., [24] a total of 239 patients (60 without
DM and 179 with DM) underwent planned a per-
cutaneous intervention of de novo coronary artery
lesions were enrolled in this study. Follow-up was
performed at 6 and 12 months. The primary end
point of the study was the need for TVR (surgical
or percutaneous) at 12 months. Secondary end
points included post-procedural cardiac death,
myocardial infarction (MI), recurrent angina,
stroke, congestive heart failure (CHF), renal fail-
ure, and cardiac re-hospitalization.
Diabetic patients with A1c >7% had a signifi-
cantly higher rate of target vessel revasculariza-
tion (TVR) than non diabetic patients (34% vs.
18%, p-value = 0.02). This percentage is higher in
Roberto A. Corpus et al. study [24] than that of
our study (at 6 months diabetics = 14.5%), which
can be due to higher mean age was (63 ± 11 years),
longer follow-up interval and larger study
population.Conclusion
Prediabetes, though not a disease entity by it-
self, is associated with of risk for both macrovascu-
lar and increasingly, microvascular pathology. It is
important to identify these conditions to prevent
incident diabetes and to take measures to stop
the vascular complications. Our study findings re-
vealed that complications of diabetes may begin
as early as patients are suffering impaired glucose
homeostasis, which warrants further evaluation in
larger studies, and may change our perception of
the management including the way of
revascularization.References
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